Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $0.0.

  • Akebia Therapeutics' EPS (Basic) rose 10203.94% to $0.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.08, marking a year-over-year increase of 6521.74%. This contributed to the annual value of -$0.33 for FY2024, which is 1879.39% down from last year.
  • Akebia Therapeutics' EPS (Basic) amounted to $0.0 in Q3 2025, which was up 10203.94% from $0.0 recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' EPS (Basic) registered a high of $0.16 during Q2 2022, and its lowest value of -$0.51 during Q2 2021.
  • In the last 5 years, Akebia Therapeutics' EPS (Basic) had a median value of -$0.09 in 2024 and averaged -$0.15.
  • As far as peak fluctuations go, Akebia Therapeutics' EPS (Basic) tumbled by 340058.75% in 2024, and later surged by 13333.33% in 2025.
  • Quarter analysis of 5 years shows Akebia Therapeutics' EPS (Basic) stood at -$0.42 in 2021, then surged by 91.61% to -$0.04 in 2022, then soared by 109.2% to $0.0 in 2023, then plummeted by 3400.59% to -$0.11 in 2024, then soared by 101.89% to $0.0 in 2025.
  • Its last three reported values are $0.0 in Q3 2025, $0.0 for Q2 2025, and $0.03 during Q1 2025.